Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Veradigm ( (MDRX) ).
On January 15, 2026, Veradigm Inc. entered into a second amendment to its existing Stockholder Agreement with Charles Myers and Jessica Myers, extending Charles Myers’ role as an observer to the company’s board of directors through July 26, 2026. The move follows earlier amendments in July 2024 and July 2025 that had progressively extended the agreement’s termination date and reflects the company’s acknowledgment of Myers’ contributions in the observer role to date. The latest amendment also allows Veradigm and the Myers parties, by mutual consent, to further extend the agreement’s termination date to January 26, 2027, signaling the company’s continued reliance on Myers’ input in its board-level deliberations and governance process.
The most recent analyst rating on (MDRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Veradigm stock, see the MDRX Stock Forecast page.
More about Veradigm
Veradigm Inc. operates in the healthcare technology sector, providing data-driven health IT solutions that support clinical, financial, and operational needs across the healthcare ecosystem. The company typically focuses on delivering tools and platforms that help providers, payers, and life sciences organizations improve care coordination and outcomes through better use of health data and analytics.
Average Trading Volume: 155,068
Technical Sentiment Signal: Strong Sell
Current Market Cap: $500.9M
Find detailed analytics on MDRX stock on TipRanks’ Stock Analysis page.